Myovant Sciences (MYOV)

Last Closing Price: 26.89 (2023-02-01)

Company Description

Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $230.97M
Net Income (Most Recent Fiscal Year) $-205.98M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 6.90
Price to Book Ratio (Most Recent Quarterly Book Value per Share) --
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -42.81%
Net Margin (Trailing 12 Months) -48.47%
Return on Equity (Trailing 12 Months) --
Return on Assets (Trailing 12 Months) -39.36%
Current Ratio (Most Recent Fiscal Quarter) 1.57
Quick Ratio (Most Recent Fiscal Quarter) 1.45
Debt to Common Equity (Most Recent Fiscal Quarter) --
Inventory Turnover (Trailing 12 Months) 1.02
Book Value per Share (Most Recent Fiscal Quarter) $-5.74
Earnings per Share (Most Recent Fiscal Quarter) $-0.59
Earnings per Share (Most Recent Fiscal Year) $-2.22
Diluted Earnings per Share (Trailing 12 Months) $-1.91
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 97.24M
Free Float 95.39M
Market Capitalization $2.61B
Average Volume (Last 20 Days) 1.08M
Beta (Past 60 Months) 2.16
Percentage Held By Insiders (Latest Annual Proxy Report) 1.90%
Percentage Held By Institutions (Latest 13F Reports) 30.62%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%